Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod
Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Pfizer's Ibrance still dominates the category but sales slowed in the first quarter, while Novartis’s Kisqali and Lilly's Verzenio both grew double digits.
Data from the PENELOPE-B study in high-risk early breast cancer patients show no separation from placebo, compounding the earlier failure of the PALLAS trial in low- and high-risk patients.